Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy

Radiother Oncol. 2021 Nov 25:S0167-8140(21)09005-8. doi: 10.1016/j.radonc.2021.11.012. Online ahead of print.ABSTRACTThe immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive conditions. Antibody testing may be useful to identify candidates for additional vaccine doses.PMID:34838892 | DOI:10.1016/j.radonc.2021.11.012

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - November 28, 2021 Category: Radiology Authors: Cynthia L Bowes Vivek Naranbhai Kerri J St Denis Evan C Lam Brittany Bertaux Florence K Keane Melin J Khandekar Alejandro B Balazs John A Iafrate Justin F Gainor Henning Willers Source Type: research